Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-06-13
2006-06-13
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S133100, C424S130100, C424S134100, C424S138100, C424S141100, C424S155100, C424S174100, C424S178100, C424S181100, C424S001490, C530S350000, C530S387100, C530S387300, C530S387700, C530S388100, C530S388220, C530S388800, C530S389100, C530S389700, C530S391100, C530S391300, C530S391700
Reexamination Certificate
active
07060272
ABSTRACT:
The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity.
REFERENCES:
patent: 5763223 (1998-06-01), Wiley et al.
patent: 6342363 (2002-01-01), Ni et al.
patent: 6433147 (2002-08-01), Ni et al.
patent: 6461823 (2002-10-01), Ni et al.
patent: 2003/0036168 (2003-02-01), Ni et al.
patent: 2003/0108516 (2003-06-01), Ni et al.
patent: 0 857 782 (1998-08-01), None
patent: WO 97/01633 (1997-01-01), None
patent: WO 98/32856 (1998-07-01), None
patent: WO 99/02653 (1999-01-01), None
patent: WO 99/11791 (1999-03-01), None
patent: WO 99/37684 (1999-07-01), None
Chantry, D., “Tumour necrosis factor antagonists,”Emerging Drugs 4:5-13, Ashley Publications Ltd (1999).
Delgado, C., et. al., “Quantitative analysis of polyethylene glycol (PEG) in PEG-modified proteins/cytokines by aqueous two-phase systems,”J. Biochem. Biophys. Methods 29:237-250, Elsevier Science (1994).
Kim, K., et. al., “Molecular determinants of response to TRAIL combined with chemotherapy in killing of normal cancer cells,”Proceedings of the American Association for Cancer Research Annual Meeting40:486, 90thAnnual Meeting of the American Association for Cancer Research (Apr. 1999).
Marsters, S.A., et. al., “Control of Apoptosis Signaling by Apo2 Ligand,”Recent Progress in Hormone Research 54:225-234, The Endocrine Society (1999).
International Search Report for International Application No. PCT/US 98/01464, European Patent Office, Netherlands, mailed on Jun. 17, 1998.
Supplementary Partial European Search Report for European Application No. EP 00 93 2061, European Patent Office, Netherlands, completed on Aug. 23, 2004.
Chinnaiyan, A.M., et al., “Signal Transduction by DR3, a Death Domain-Containing Receptor Related to TNFR-1 and CD95,”Science 274:990-992, American Association for the Advancement of Science (Nov. 1996).
EMBL Database, Accession No. AA100865, Hillier, L., et al., European Molecular Biology Laboratory (Oct. 30, 1996).
Goodman, J.W., “Immunogens & Antigens,” inBasic&Clinical Immunology, Stites, D.P., et al., eds., Appleton & Lange, Norwalk, CT, pp. 50-57 (1988).
Lerner, R.A., “Antibodies of Predetermined Specificity in Biology and Medicine,”Adv. Immunol. 36:1-44, Academic Press (1984).
NCBI Entrez, GenBank Report, Accession No. AA102383, Hillier, L., et al., National Center for Biotechnology Information (Oct. 28, 1996).
NCBI Entrez, GenBank Report, Accession No. W65310, Hillier, L., et al., National Center for Biotechnology Information (Oct. 15, 1996).
NCBI Entrez, GenBank Report, Accession No. AA102745, Hillier, L., et al., National Center for Biotechnology Information (Oct. 28, 1996).
NCBI Entrez, GenBank Report, Accession No. AA102746, Hillier, L., et al., National Center for Biotechnology Information (Oct. 28, 1996).
NCBI Entrez, GenBank Report, Accession No. AA150849, Hillier, L., et al., National Center for Biotechnology Information (Dec. 10, 1996).
NCBI Entrez, GenBank Report, Accession No. AA639619, Strausberg, R., National Center for Biotechnology Information (Oct. 23, 1997).
Pan, G., et al., “The Receptor for the Cytotoxic Ligand TRAIL,”Science 276:111-113, American Association for the Advancement of Science (1997).
Ruf, M., and Kössel, H., “Structure and Expression of the Gene Coding for the α-Subunit of DNA-Dependent RNA Polymerase from the Chloroplast Genome ofZea Mays,” Nucl. Acids Res. 16:5741-5754, Oxford University Press (1988).
Strader, C.D., et al., “Structural basis of β-adrenergic receptor function,”FASEB J. 3:1825-1832, Federation of American Societies for Experimental Biology (1989).
Walczak, H., et al., “TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL,”EMBO J. 16:5386-5397, Oxford University Press (1997).
Dixit Vishva M
Gentz Reiner L
Ni Jian
Pan James G
Rosen Craig A
Human Genome Sciences Inc.
Kaufman Claire
Spector Lorraine
Sterne Kessler Goldstein & Fox P.L.L.C.
The Regents of the University of Michigan
LandOfFree
Death domain containing receptor-4 agonist antibodies and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Death domain containing receptor-4 agonist antibodies and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Death domain containing receptor-4 agonist antibodies and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3618579